Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06483659 · ClinicalTrials.gov registry record · Phase 2

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

A Phase 2 study of Postoperative Pain, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 2
Development phase
152
Enrollment target
1
Study location

NCT06483659 is a Phase 2 study of Postoperative Pain that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 152 participants, below the 229-participant average among 63 other Postoperative Pain trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06483659, a Phase 2 study of Postoperative Pain, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 2
Development phase
152 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blinded, placebo-controlled trial to compare the effectiveness of IV oxytocin infusion to placebo on peri-operative opioid consumption and reducing post-operative pain following a minimally invasive hysterectomy under general anesthesia.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Oxytocin

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2025-06-01
Est. Completion 2026-12-01
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT06483659

The ClinicalTrials.gov registry entry for NCT06483659 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 63 other Postoperative Pain trials with a reported enrollment target (34% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postoperative Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06483659 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06483659 about?

NCT06483659 is a clinical study titled "Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy". This is a randomized, double-blinded, placebo-controlled trial to compare the effectiveness of IV oxytocin infusion to placebo on peri-operative opioid consumption and reducing post-operative pain following a minimally invasive hysterectomy under general anesthesia.

What is the current status of trial NCT06483659?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2025-06-01. Estimated completion is 2026-12-01.

What conditions does trial NCT06483659 study?

This clinical trial studies the following conditions: Postoperative Pain.

What interventions are being tested in trial NCT06483659?

The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).

Who is sponsoring clinical trial NCT06483659?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06483659 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.